Literature DB >> 26231081

Lowering the pKa of a bisimidazoline lead with halogen atoms results in improved activity and selectivity against Trypanosoma brucei in vitro.

Carlos H Ríos Martínez1, J Jonathan Nué Martínez1, Godwin U Ebiloma2, Harry P de Koning2, Ibon Alkorta1, Christophe Dardonville3.   

Abstract

Diphenyl-based bis(2-iminoimidazolidines) are promising antiprotozoal agents that are curative in mouse models of stage 1 trypanosomiasis but devoid of activity in the late-stage disease, possibly due to poor brain penetration caused by their dicationic nature. We present here a strategy consisting in reducing the pKa of the basic 2-iminoimidazolidine groups though the introduction of chlorophenyl, fluorophenyl and pyridyl ring in the structure of the trypanocidal lead 4-(imidazolidin-2-ylideneamino)-N-(4-(imidazolidin-2-ylideneamino)phenyl)benzamide (1). The new compounds showed reduced pKa values (in the range 1-3 pKa units) for the imidazolidine group linked to the substituted phenyl ring. In vitro activities (EC50) against wild type and resistant strains of T. b. brucei (s427 and B48, respectively) were in the submicromolar range with four compounds being more active and selective than 1 (SI > 340). In particular, the two most potent compounds (3b and 5a) acted approximately 6-times faster than 1 to kill trypanosomes in vitro. No cross-resistance with the diamidine and melaminophenyl class of trypanocides was observed indicating that these compounds represent interesting leads for further in vivo studies.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Dibasic compound; Halogen scan; Imidazoline; T. brucei; pK(a)

Mesh:

Substances:

Year:  2015        PMID: 26231081     DOI: 10.1016/j.ejmech.2015.07.013

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast.

Authors:  Cinthia R Millan; Francisco J Acosta-Reyes; Laura Lagartera; Godwin U Ebiloma; Leandro Lemgruber; J Jonathan Nué Martínez; Núria Saperas; Christophe Dardonville; Harry P de Koning; J Lourdes Campos
Journal:  Nucleic Acids Res       Date:  2017-08-21       Impact factor: 16.971

2.  An aromatic imidazoline derived from chloroquinoline triggers cell cycle arrest and inhibits with high selectivity the Trypanosoma cruzi mammalian host-cells infection.

Authors:  Roberto I Cuevas-Hernández; Richard M B M Girard; Luka Krstulović; Miroslav Bajić; Ariel Mariano Silber
Journal:  PLoS Negl Trop Dis       Date:  2021-11-29

3.  Imidazoline- and Benzamidine-Based Trypanosome Alternative Oxidase Inhibitors: Synthesis and Structure-Activity Relationship Studies.

Authors:  David Cisneros; Eduardo J Cueto-Díaz; Tania Medina-Gil; Rebecca Chevillard; Teresa Bernal-Fraile; Ramón López-Sastre; Mustafa M Aldfer; Marzuq A Ungogo; Hamza A A Elati; Natsumi Arai; Momoka Otani; Shun Matsushiro; Chiaki Kojima; Godwin U Ebiloma; Tomoo Shiba; Harry P de Koning; Christophe Dardonville
Journal:  ACS Med Chem Lett       Date:  2022-01-28       Impact factor: 4.345

4.  Multi-target mode of action of a Clerodane-type diterpenoid from Polyalthia longifolia targeting African trypanosomes.

Authors:  Godwin U Ebiloma; Evangelos Katsoulis; John O Igoli; Alexander I Gray; Harry P De Koning
Journal:  Sci Rep       Date:  2018-03-15       Impact factor: 4.379

5.  Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs.

Authors:  Jens Hagenow; Stefanie Hagenow; Kathrin Grau; Mohammad Khanfar; Lena Hefke; Ewgenij Proschak; Holger Stark
Journal:  Drug Des Devel Ther       Date:  2020-01-28       Impact factor: 4.162

6.  Direct, Late-Stage Mono-N-arylation of Pentamidine: Method Development, Mechanistic Insight, and Expedient Access to Novel Antiparastitics against Diamidine-Resistant Parasites.

Authors:  Jack Robertson; Marzuq A Ungogo; Mustafa M Aldfer; Leandro Lemgruber; Fergus S McWhinnie; Bela E Bode; Katherine L Jones; Allan J B Watson; Harry P de Koning; Glenn A Burley
Journal:  ChemMedChem       Date:  2021-09-02       Impact factor: 3.540

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.